Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2
Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Mod...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
S. V. Nedogoda [verfasserIn] A. S. Salasyuk [verfasserIn] I. N. Barikina [verfasserIn] V. O. Smirnova [verfasserIn] M. Yu. Frolov [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Качественная клиническая практика - Izdatelstvo OKI, 2020, (2020), 3, Seite 13-22 |
|---|---|
| Übergeordnetes Werk: |
year:2020 ; number:3 ; pages:13-22 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.24411/2588-0519-2019-10079 |
|---|
| Katalog-ID: |
DOAJ077778820 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ077778820 | ||
| 003 | DE-627 | ||
| 005 | 20240413174544.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.24411/2588-0519-2019-10079 |2 doi | |
| 035 | |a (DE-627)DOAJ077778820 | ||
| 035 | |a (DE-599)DOAJ553a6426cd0e47598d8fec61af138875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a R855-855.5 | |
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a S. V. Nedogoda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks. | ||
| 650 | 4 | |a сахарный диабет 2-го типа | |
| 650 | 4 | |a инсулин гларгин | |
| 650 | 4 | |a ликсисенатид | |
| 650 | 4 | |a оценка технологии здравоохранения | |
| 653 | 0 | |a Medical technology | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a A. S. Salasyuk |e verfasserin |4 aut | |
| 700 | 0 | |a I. N. Barikina |e verfasserin |4 aut | |
| 700 | 0 | |a V. O. Smirnova |e verfasserin |4 aut | |
| 700 | 0 | |a M. Yu. Frolov |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Качественная клиническая практика |d Izdatelstvo OKI, 2020 |g (2020), 3, Seite 13-22 |w (DE-627)1760591807 |x 26188473 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g number:3 |g pages:13-22 |
| 856 | 4 | 0 | |u https://doi.org/10.24411/2588-0519-2019-10079 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/553a6426cd0e47598d8fec61af138875 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.clinvest.ru/jour/article/view/463 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2588-0519 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2618-8473 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2020 |e 3 |h 13-22 | ||
| author_variant |
s v n svn a s s ass i n b inb v o s vos m y f myf |
|---|---|
| matchkey_str |
article:26188473:2020----::cnmcvlainfhfxdobntooislnlrienlxsnt |
| hierarchy_sort_str |
2020 |
| callnumber-subject-code |
R |
| publishDate |
2020 |
| allfields |
10.24411/2588-0519-2019-10079 doi (DE-627)DOAJ077778820 (DE-599)DOAJ553a6426cd0e47598d8fec61af138875 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 S. V. Nedogoda verfasserin aut Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks. сахарный диабет 2-го типа инсулин гларгин ликсисенатид оценка технологии здравоохранения Medical technology Pharmacy and materia medica A. S. Salasyuk verfasserin aut I. N. Barikina verfasserin aut V. O. Smirnova verfasserin aut M. Yu. Frolov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2020), 3, Seite 13-22 (DE-627)1760591807 26188473 nnns year:2020 number:3 pages:13-22 https://doi.org/10.24411/2588-0519-2019-10079 kostenfrei https://doaj.org/article/553a6426cd0e47598d8fec61af138875 kostenfrei https://www.clinvest.ru/jour/article/view/463 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 3 13-22 |
| spelling |
10.24411/2588-0519-2019-10079 doi (DE-627)DOAJ077778820 (DE-599)DOAJ553a6426cd0e47598d8fec61af138875 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 S. V. Nedogoda verfasserin aut Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks. сахарный диабет 2-го типа инсулин гларгин ликсисенатид оценка технологии здравоохранения Medical technology Pharmacy and materia medica A. S. Salasyuk verfasserin aut I. N. Barikina verfasserin aut V. O. Smirnova verfasserin aut M. Yu. Frolov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2020), 3, Seite 13-22 (DE-627)1760591807 26188473 nnns year:2020 number:3 pages:13-22 https://doi.org/10.24411/2588-0519-2019-10079 kostenfrei https://doaj.org/article/553a6426cd0e47598d8fec61af138875 kostenfrei https://www.clinvest.ru/jour/article/view/463 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 3 13-22 |
| allfields_unstemmed |
10.24411/2588-0519-2019-10079 doi (DE-627)DOAJ077778820 (DE-599)DOAJ553a6426cd0e47598d8fec61af138875 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 S. V. Nedogoda verfasserin aut Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks. сахарный диабет 2-го типа инсулин гларгин ликсисенатид оценка технологии здравоохранения Medical technology Pharmacy and materia medica A. S. Salasyuk verfasserin aut I. N. Barikina verfasserin aut V. O. Smirnova verfasserin aut M. Yu. Frolov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2020), 3, Seite 13-22 (DE-627)1760591807 26188473 nnns year:2020 number:3 pages:13-22 https://doi.org/10.24411/2588-0519-2019-10079 kostenfrei https://doaj.org/article/553a6426cd0e47598d8fec61af138875 kostenfrei https://www.clinvest.ru/jour/article/view/463 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 3 13-22 |
| allfieldsGer |
10.24411/2588-0519-2019-10079 doi (DE-627)DOAJ077778820 (DE-599)DOAJ553a6426cd0e47598d8fec61af138875 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 S. V. Nedogoda verfasserin aut Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks. сахарный диабет 2-го типа инсулин гларгин ликсисенатид оценка технологии здравоохранения Medical technology Pharmacy and materia medica A. S. Salasyuk verfasserin aut I. N. Barikina verfasserin aut V. O. Smirnova verfasserin aut M. Yu. Frolov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2020), 3, Seite 13-22 (DE-627)1760591807 26188473 nnns year:2020 number:3 pages:13-22 https://doi.org/10.24411/2588-0519-2019-10079 kostenfrei https://doaj.org/article/553a6426cd0e47598d8fec61af138875 kostenfrei https://www.clinvest.ru/jour/article/view/463 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 3 13-22 |
| allfieldsSound |
10.24411/2588-0519-2019-10079 doi (DE-627)DOAJ077778820 (DE-599)DOAJ553a6426cd0e47598d8fec61af138875 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 S. V. Nedogoda verfasserin aut Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks. сахарный диабет 2-го типа инсулин гларгин ликсисенатид оценка технологии здравоохранения Medical technology Pharmacy and materia medica A. S. Salasyuk verfasserin aut I. N. Barikina verfasserin aut V. O. Smirnova verfasserin aut M. Yu. Frolov verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2020), 3, Seite 13-22 (DE-627)1760591807 26188473 nnns year:2020 number:3 pages:13-22 https://doi.org/10.24411/2588-0519-2019-10079 kostenfrei https://doaj.org/article/553a6426cd0e47598d8fec61af138875 kostenfrei https://www.clinvest.ru/jour/article/view/463 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 3 13-22 |
| language |
Russian |
| source |
In Качественная клиническая практика (2020), 3, Seite 13-22 year:2020 number:3 pages:13-22 |
| sourceStr |
In Качественная клиническая практика (2020), 3, Seite 13-22 year:2020 number:3 pages:13-22 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
сахарный диабет 2-го типа инсулин гларгин ликсисенатид оценка технологии здравоохранения Medical technology Pharmacy and materia medica |
| isfreeaccess_bool |
true |
| container_title |
Качественная клиническая практика |
| authorswithroles_txt_mv |
S. V. Nedogoda @@aut@@ A. S. Salasyuk @@aut@@ I. N. Barikina @@aut@@ V. O. Smirnova @@aut@@ M. Yu. Frolov @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
1760591807 |
| id |
DOAJ077778820 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ077778820</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174544.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.24411/2588-0519-2019-10079</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ077778820</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ553a6426cd0e47598d8fec61af138875</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">S. V. Nedogoda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сахарный диабет 2-го типа</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин гларгин</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ликсисенатид</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">оценка технологии здравоохранения</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Salasyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. N. Barikina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. O. Smirnova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Yu. Frolov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Качественная клиническая практика</subfield><subfield code="d">Izdatelstvo OKI, 2020</subfield><subfield code="g">(2020), 3, Seite 13-22</subfield><subfield code="w">(DE-627)1760591807</subfield><subfield code="x">26188473</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:13-22</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.24411/2588-0519-2019-10079</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/553a6426cd0e47598d8fec61af138875</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.clinvest.ru/jour/article/view/463</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2588-0519</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8473</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">13-22</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
S. V. Nedogoda |
| spellingShingle |
S. V. Nedogoda misc R855-855.5 misc RS1-441 misc сахарный диабет 2-го типа misc инсулин гларгин misc ликсисенатид misc оценка технологии здравоохранения misc Medical technology misc Pharmacy and materia medica Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 |
| authorStr |
S. V. Nedogoda |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760591807 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
R855-855 |
| illustrated |
Not Illustrated |
| issn |
26188473 |
| topic_title |
R855-855.5 RS1-441 Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 сахарный диабет 2-го типа инсулин гларгин ликсисенатид оценка технологии здравоохранения |
| topic |
misc R855-855.5 misc RS1-441 misc сахарный диабет 2-го типа misc инсулин гларгин misc ликсисенатид misc оценка технологии здравоохранения misc Medical technology misc Pharmacy and materia medica |
| topic_unstemmed |
misc R855-855.5 misc RS1-441 misc сахарный диабет 2-го типа misc инсулин гларгин misc ликсисенатид misc оценка технологии здравоохранения misc Medical technology misc Pharmacy and materia medica |
| topic_browse |
misc R855-855.5 misc RS1-441 misc сахарный диабет 2-го типа misc инсулин гларгин misc ликсисенатид misc оценка технологии здравоохранения misc Medical technology misc Pharmacy and materia medica |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Качественная клиническая практика |
| hierarchy_parent_id |
1760591807 |
| hierarchy_top_title |
Качественная клиническая практика |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760591807 |
| title |
Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 |
| ctrlnum |
(DE-627)DOAJ077778820 (DE-599)DOAJ553a6426cd0e47598d8fec61af138875 |
| title_full |
Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 |
| author_sort |
S. V. Nedogoda |
| journal |
Качественная клиническая практика |
| journalStr |
Качественная клиническая практика |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
13 |
| author_browse |
S. V. Nedogoda A. S. Salasyuk I. N. Barikina V. O. Smirnova M. Yu. Frolov |
| class |
R855-855.5 RS1-441 |
| format_se |
Elektronische Aufsätze |
| author-letter |
S. V. Nedogoda |
| doi_str_mv |
10.24411/2588-0519-2019-10079 |
| author2-role |
verfasserin |
| title_sort |
economic evaluation of the fixed combination of insulin glargine and lixisenatide in diabetes mellitus type 2 |
| callnumber |
R855-855.5 |
| title_auth |
Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 |
| abstract |
Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks. |
| abstractGer |
Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks. |
| abstract_unstemmed |
Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
3 |
| title_short |
Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2 |
| url |
https://doi.org/10.24411/2588-0519-2019-10079 https://doaj.org/article/553a6426cd0e47598d8fec61af138875 https://www.clinvest.ru/jour/article/view/463 https://doaj.org/toc/2588-0519 https://doaj.org/toc/2618-8473 |
| remote_bool |
true |
| author2 |
A. S. Salasyuk I. N. Barikina V. O. Smirnova M. Yu. Frolov |
| author2Str |
A. S. Salasyuk I. N. Barikina V. O. Smirnova M. Yu. Frolov |
| ppnlink |
1760591807 |
| callnumber-subject |
R - General Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.24411/2588-0519-2019-10079 |
| callnumber-a |
R855-855.5 |
| up_date |
2024-07-03T14:03:55.990Z |
| _version_ |
1803566905814941696 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ077778820</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174544.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.24411/2588-0519-2019-10079</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ077778820</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ553a6426cd0e47598d8fec61af138875</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">S. V. Nedogoda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2DM) in the real practice.Materials and Methods. Model of Burden of T2DM has been created in Microsoft Excel 2010 program. Direct (costs of medicines, treatment of main T2DM complications — myocardial infarction, stroke, etc.) as well as indirect costs (GPD losses, disability related payments, etc.) were calculated. Complications’ rate was took from Federal Diabetes Register. Influence on Burden of T2DM was tested with the additional model which can calculate expenditures with different drugs including Soliqua SoloStar® usage.Results. Direct medical costs with Soliqua SoloStar® usage were less in compare with insulin glargine 100 UI/ml on 23,5 % per year due to decreasing level of severe hypoglycemia and possible protective effect on complications of T2DM (better control). Total expenditures for Soliqua SoloStar® were less on 2,5 % annually, in the same time insulin glargine led to total cost increase by 18,4 % per year. So, difference between expenditures in case of Soliqua SoloStar® were less on appr 21 % vs insulin glargine 100 UI/ml. Budget saving is expected as 6,78 ml RUR per year / 1 000 patients in case of Soliqua SoloStar® usage.Conclusion. Soliqua SoloStar® has economic benefits due to T2DM complications and severe hypoglycemia reduction risks.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сахарный диабет 2-го типа</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин гларгин</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ликсисенатид</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">оценка технологии здравоохранения</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Salasyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. N. Barikina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. O. Smirnova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Yu. Frolov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Качественная клиническая практика</subfield><subfield code="d">Izdatelstvo OKI, 2020</subfield><subfield code="g">(2020), 3, Seite 13-22</subfield><subfield code="w">(DE-627)1760591807</subfield><subfield code="x">26188473</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:13-22</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.24411/2588-0519-2019-10079</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/553a6426cd0e47598d8fec61af138875</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.clinvest.ru/jour/article/view/463</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2588-0519</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8473</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">13-22</subfield></datafield></record></collection>
|
| score |
7.4021244 |